Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center

Articles by Grzegorz S. Nowakowski, MD

A panel of 6 experts on follicular lymphoma and mantle cell lymphoma seated at a long desk

ASH 2023 Updates on Frontline Therapies in FL

ByGrzegorz S. Nowakowski, MD,Jennifer Crombie, MD,Matthew A. Lunning, DO, FACP,Peter Martin, MD,Laurie H. Sehn, MD, MPH,Bijal D. Shah, MD

January 2nd 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

A panel of 6 experts on follicular lymphoma seated at a long table

Current Treatment Options in First-line FL

ByGrzegorz S. Nowakowski, MD,Jennifer Crombie, MD,Matthew A. Lunning, DO, FACP,Peter Martin, MD,Laurie H. Sehn, MD, MPH,Bijal D. Shah, MD

December 18th 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Role of Bispecifics and Future Promising Treatments in DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

August 11th 2022

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

The Future of DLBCL Treatment

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

August 11th 2022

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

Management and Work-up of Patients for Salvage Therapy

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Therapeutic Sequencing and Bridging in DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 22nd 2022

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Treating Patients Who Relapse or Progress on CAR T-Cell Therapy

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 22nd 2022

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 18th 2022

Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.

Comparing Real-World Evidence With Data From Clinical Trials

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 18th 2022

The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.

Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 7th 2022

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

July 7th 2022

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

Improving Outcomes in Patients With DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

June 30th 2022

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

A Focus on Frontline Treatment in Patients With DLBCL

ByGrzegorz S. Nowakowski, MD,Frederick Locke, MD,Caron Jacobson, MD,Matthew A. Lunning, DO, FACP,Leo I. Gordon, MD

June 30th 2022

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Concluding Thoughts on the DLBCL Treatment Landscape

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Grzegorz S. Nowakowski, MD,Richard T. Maziarz, MD

February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Monoclonal Antibodies for Treatment of R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Real-World Data With CAR-T Therapies in R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Safety With CAR-T Therapies in R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

CAR-T Therapy

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

ByKami J. Maddocks, MD,Jason Westin, MD,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD,David Miklos, MD, Stanford University

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

Front-Line Treatment of DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

ByGrzegorz S. Nowakowski, MD

September 22nd 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

ByGrzegorz S. Nowakowski, MD

August 18th 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL

ByGrzegorz S. Nowakowski, MD

August 12th 2020

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD

Articles by Grzegorz S. Nowakowski, MD

ASH 2023 Updates on Frontline Therapies in FL

Current Treatment Options in First-line FL

Role of Bispecifics and Future Promising Treatments in DLBCL

The Future of DLBCL Treatment

Management and Work-up of Patients for Salvage Therapy

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

Therapeutic Sequencing and Bridging in DLBCL

Treating Patients Who Relapse or Progress on CAR T-Cell Therapy

A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape

Comparing Real-World Evidence With Data From Clinical Trials

Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

Improving Outcomes in Patients With DLBCL

A Focus on Frontline Treatment in Patients With DLBCL

Concluding Thoughts on the DLBCL Treatment Landscape

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

Monoclonal Antibodies for Treatment of R/R DLBCL

Real-World Data With CAR-T Therapies in R/R DLBCL

Safety With CAR-T Therapies in R/R DLBCL

CAR-T Therapies in R/R DLBCL

CAR-T Therapy

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Front-Line Treatment of DLBCL

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies